Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Krüger, B. Ehrlein, M. Zier, R. Greguletz (Bad Homburg, Germany). Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Respir J 2014; 44: Suppl. 58, 4635

Member's Comments

No comment yet.

Related content which might interest you: Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Prevalence of serious post-training inhaler technique errors made by device-naïve patients using three different dry powder inhalers (DPIs) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Delivery of medication by breath-actuated nebulizer (BAN) is similar when used with differing inhalation / exhalation ratios: A contrast to breath enhanced nebulizer (BEN) behavior Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Are extra-fine particles from dry powder inhalers likely to improve lung deposition? Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Innovative dry powder inhaler (DPI) shows improved cost-effectiveness compared with current DPIs for asthma therapy in UK primary care Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Preference, satisfaction and critical errors with Genuair® and Breezhaler® in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Satisfaction survey on the use of breath actuated Inhaler Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 Impact of inhaler technique on patient outcomes in asthma patients using diskus in primary care Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease? Year: 2014 Valved holding chambers (VHCs) can have different medication delivery performance as a function of delay interval following actuation of the pressurized metered dose inhaler (pMDI) Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthma Source: International Congress 2016 – Asthma management Year: 2016 Comparing pharmacist time use for asthma and COPD patients using various types of inhaler devices Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Inhaler competence and patient satisfaction with a DPI; results of two real-life studies in asthma and COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013